Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension (UNISUS)

Purpose of Study:

To demonstrate superiority of macitentan 75 mg in prolonging the time to the first Clinical Events Committee (CEC)- adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg

Study Dates:
June 30, 2020 - September 21, 2026

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Sponsors:

Actelion Pharmaceuticals Ltd*

ClinicalTrails.gov Identifier:
NCT04273945

Register for Trial